Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Excess weight mediates changes in HDL pool that reduce cholesterol efflux capacity and increase antioxidant activity.
de Lima-Junior JC, Virginio VWM, Moura FA, Bertolami A, Bertolami M, Coelho-Filho OR, Zanotti I, Nadruz W, de Faria EC, de Carvalho LSF, Sposito AC. de Lima-Junior JC, et al. Among authors: de faria ec, de carvalho lsf. Nutr Metab Cardiovasc Dis. 2020 Feb 10;30(2):254-264. doi: 10.1016/j.numecd.2019.09.017. Epub 2019 Sep 23. Nutr Metab Cardiovasc Dis. 2020. PMID: 31753789
Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus.
Wolf VLW, Breder I, de Carvalho LSF, Soares AAS, Cintra RM, Barreto J, Munhoz DB, Kimura-Medorima ST, Nadruz W, Guerra-Júnior G, Quinaglia T, Muscelli E, Sposito AC; Addenda-BHS2 trial investigators. Wolf VLW, et al. Among authors: de carvalho lsf. Nutr Diabetes. 2021 Jun 12;11(1):17. doi: 10.1038/s41387-021-00160-5. Nutr Diabetes. 2021. PMID: 34120150 Free PMC article. Clinical Trial.
Dapagliflozin reduces adiposity and increases adiponectin in patients with type 2 diabetes and atherosclerotic disease at short-term: An active-controlled randomised trial.
Breder I, Wolf VLW, Soares AAS, de Carvalho LSF, Kimura-Medorima ST, Cintra RM, Barreto J, Munhoz DB, Cunha JS, Bonilha I, Coelho-Filho OR, Quinaglia T, Nadruz W, Guerra-Junior G, Muscelli E, Sposito AC; ADDENDA-BHS2 Trial Investigators. Breder I, et al. Among authors: de carvalho lsf. Diabetes Metab. 2022 Mar;48(2):101304. doi: 10.1016/j.diabet.2021.101304. Epub 2021 Nov 19. Diabetes Metab. 2022. PMID: 34808345 Clinical Trial. No abstract available.
Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial.
Sposito AC, Breder I, Barreto J, Breder J, Bonilha I, Lima M, Oliveira A, Wolf V, Luchiari B, do Carmo HR, Munhoz D, Oliveira D, Coelho-Filho OR, Coelho OR, Matos-Souza JR, Moura FA, de Carvalho LSF, Nadruz W, Quinaglia T, Kimura-Medorima ST; EXCEED-BHS3 Group. Sposito AC, et al. Among authors: de carvalho lsf. Cardiovasc Diabetol. 2022 Aug 6;21(1):147. doi: 10.1186/s12933-022-01584-8. Cardiovasc Diabetol. 2022. PMID: 35933413 Free PMC article. Clinical Trial.
Comparative effectiveness and cost-effectiveness of cardioprotective glucose-lowering therapies for type 2 diabetes in Brazil: a Bayesian network model.
Nogueira ACC, Barreto J, Moura FA, Luchiari B, Abuhab A, Bonilha I, Nadruz W, Gaziano JM, Gaziano T, de Carvalho LSF, Sposito AC; Brazilian Heart Study Group. Nogueira ACC, et al. Among authors: de carvalho lsf. Health Econ Rev. 2023 Oct 25;13(1):50. doi: 10.1186/s13561-023-00466-3. Health Econ Rev. 2023. PMID: 37878108 Free PMC article.
27 results